Mirati falls, as Phase III sitravatinib combo trial flops

25 May 2023

Shares of US oncology drugmaker Mirati Therapeutics (Nasdaq: MRTX) closed down 4% on Wednesday and were a further 8.7% lower at $40.01 in pre-market activity today, after it revealed that the SAPPHIRE study did not meet its primary endpoint of overall survival (OS) at the final analysis.

SAPPHIRE is a Phase III study evaluating sitravatinib in combination with nivolumab (Bristol Myers Squibb’s [NYSE: BMY] blockbuster brand Opdivo) versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The company plans to disclose the study data at a future date.

Principal Investigators will be given the option to continue therapy for patients who are experiencing clinical benefit and would like to remain on treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK